The Department of Pharmacology and Toxicology at the College of Pharmacy, University of Basrah, organized a discussion panel titled "Mounjaro® (Tirzepatide): The First Dual GIP and GLP-1 Receptor Agonist Approved for Treating Type 2 Diabetes."
The session included a lecture by Lecturer Shaimaa Nadhem Kadhim, who explained the mechanism of Tirzepatide in lowering blood glucose levels and aiding weight loss. The medication mimics natural gastric hormones (GIP and GLP-1), stimulating insulin secretion and slowing digestion to enhance satiety.
The lecture highlighted possible side effects, ranging from nausea and digestive issues to serious risks such as acute pancreatitis or thyroid carcinoma. It was emphasized that the medication must only be used under expert medical supervision.
Special warnings were discussed for patients with a family history of Medullary Thyroid Carcinoma (MTC) or Multiple Endocrine Neoplasia type 2 (MEN 2), stressing the importance of clinical oversight and diagnostic testing to monitor the body's response.
